71
[36] Dunachie SJ, Walther M, Vuola JM, Webster DP, Keating SM, Berthoud T, et al. A
clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and
MVA-CS. Vaccine. 2006 Apr 5;24(15):2850-9.
[37] Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol.
2005 Jul 15;175(2):633-9.
[38] Ramirez JC, Gherardi MM, Esteban M. Biology of attenuated modified vaccinia virus
Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses
in comparison with the Western Reserve strain and advantages as a vaccine. J Virol. 2000
Jan;74(2):923-33.
[39] Drexler I, Staib C, Sutter G. Modified vaccinia virus Ankara as antigen delivery system:
how can we best use its potential? Curr Opin Biotechnol. 2004 Dec;15(6):506-12.
[40] Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. [MVA
vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA)
(author's transl)]. Deutsche medizinische Wochenschrift (1946). 1974 Nov 22;99(47):2386-92.
[41] Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated
vaccinia virus MVA and their influence on virulence. The Journal of general virology. 1991
May;72 ( Pt 5):1031-8.
[42] Gallego-Gomez JC, Risco C, Rodriguez D, Cabezas P, Guerra S, Carrascosa JL, et al.
Differences in virus-induced cell morphology and in virus maturation between MVA and other
strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. Journal of virology.
2003 Oct;77(19):10606-22.
[43] Hodge JW, Poole DJ, Aarts WM, Gomez Yafal A, Gritz L, Schlom J. Modified vaccinia
virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost
vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 2003 Nov
15;63(22):7942-9.
[44] Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM, et al.
Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine.
2006 May 22;24(21):4554-61.
[45] McShane H, Brookes R, Gilbert SC, Hill AV. Enhanced immunogenicity of CD4(+) t-cell
responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost
vaccination regimen for murine tuberculosis. Infect Immun. 2001 Feb;69(2):681-6.
[46] Zhang X, Cassis-Ghavami F, Eller M, Currier J, Slike BM, Chen X, et al. Direct
comparison of antigen production and induction of apoptosis by canarypox virus- and modified
vaccinia virus ankara-human immunodeficiency virus vaccine vectors. J Virol. 2007
Jul;81(13):7022-33.
[47] Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL, Gileadi U, et al. Competition
between CTL narrows the immune response induced by prime-boost vaccination protocols. J
Immunol. 2002 May 1;168(9):4391-8.
[48] McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, et al.
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified
vaccinia virus Ankara in humans. Nat Med. 2003 Jun;9(6):729-35.
[49] Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, et al. Severe acute
respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus
protectively immunizes mice. Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6.
[50] Bruna-Romero O, Lasarte JJ, Wilkinson G, Grace K, Clarke B, Borras-Cuesta F, et al.
Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a
defective recombinant adenovirus. Hepatology. 1997 Feb;25(2):470-7.
[51] Demberg T, Florese RH, Heath MJ, Larsen K, Kalisz I, Kalyanaraman VS, et al. A
replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env